--- title: "Asian Penny Stocks To Watch In April 2025" type: "News" locale: "en" url: "https://longbridge.com/en/news/234687619.md" description: "Amid global trade tensions, Asian markets are focusing on penny stocks, which may offer growth potential despite their risks. The article highlights ten penny stocks in Asia, including Interlink Telecom and Chongqing Lummy Pharmaceutical, detailing their market caps, financial health, and challenges. Companies like Shenzhen Jinjia Group and Hainan Shennong Seed Industry Technology are also discussed, showcasing their financial positions and operational challenges. Investors are encouraged to explore these lesser-known companies for potential value amidst market uncertainties." datetime: "2025-04-06T22:51:40.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/234687619.md) - [en](https://longbridge.com/en/news/234687619.md) - [zh-HK](https://longbridge.com/zh-HK/news/234687619.md) --- # Asian Penny Stocks To Watch In April 2025 Amid heightened global trade tensions, Asian markets are navigating a complex landscape influenced by recent tariff announcements. Investors are keenly observing how these developments might impact smaller companies, which often exhibit resilience and adaptability in uncertain times. Despite the vintage feel of the term "penny stocks," these investments can still offer significant potential for growth when backed by strong financials, providing an intriguing opportunity for those seeking value in lesser-known companies. ### Top 10 Penny Stocks In Asia **Name** **Share Price** **Market Cap** **Rewards & Risks** Interlink Telecom (SET:ITEL) THB1.28 THB1.78B ✅ 4 ⚠️ 5 View Analysis \> Advice IT Infinite (SET:ADVICE) THB4.32 THB2.68B ✅ 4 ⚠️ 3 View Analysis \> CNMC Goldmine Holdings (Catalist:5TP) SGD0.365 SGD147.93M ✅ 4 ⚠️ 1 View Analysis \> Beng Kuang Marine (SGX:BEZ) SGD0.193 SGD38.45M ✅ 4 ⚠️ 3 View Analysis \> Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.17 SGD8.57B ✅ 5 ⚠️ 0 View Analysis \> YesAsia Holdings (SEHK:2209) HK$3.11 HK$1.28B ✅ 4 ⚠️ 3 View Analysis \> Bosideng International Holdings (SEHK:3998) HK$4.01 HK$45.93B ✅ 4 ⚠️ 1 View Analysis \> Lever Style (SEHK:1346) HK$1.29 HK$813.93M ✅ 4 ⚠️ 1 View Analysis \> Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ✅ 4 ⚠️ 2 View Analysis \> Xiamen Hexing Packaging Printing (SZSE:002228) CN¥3.16 CN¥3.66B ✅ 3 ⚠️ 1 View Analysis \> Click here to see the full list of 1,111 stocks from our Asian Penny Stocks screener. We'll examine a selection from our screener results. ## Shenzhen Jinjia GroupLtd (SZSE:002191) **Simply Wall St Financial Health Rating:** ★★★★☆☆ **Overview:** Shenzhen Jinjia Group Co., Ltd. is involved in the research, development, and production of packaging materials in China with a market cap of CN¥5.46 billion. **Operations:** The company generates revenue primarily from its operations in China, amounting to CN¥3.18 billion. **Market Cap:** CN¥5.46B Shenzhen Jinjia Group Ltd. has recently become profitable, although its earnings have declined by 38% annually over the past five years. The company’s short-term assets of CN¥3.9 billion comfortably cover both short-term and long-term liabilities, indicating solid liquidity management. However, despite having more cash than total debt, its operating cash flow remains negative, suggesting challenges in covering debt through operations alone. The board of directors is experienced with an average tenure of 9.6 years, but recent financial results were impacted by a large one-off loss of CN¥244.9 million as of September 2024. - Jump into the full analysis health report here for a deeper understanding of Shenzhen Jinjia GroupLtd. - Examine Shenzhen Jinjia GroupLtd's earnings growth report to understand how analysts expect it to perform. SZSE:002191 Financial Position Analysis as at Apr 2025 ## Chongqing Lummy Pharmaceutical (SZSE:300006) **Simply Wall St Financial Health Rating:** ★★★★★★ **Overview:** Chongqing Lummy Pharmaceutical Co., Ltd. is involved in the research, development, manufacture, and sale of pharmaceutical products in China with a market cap of CN¥3.79 billion. **Operations:** Chongqing Lummy Pharmaceutical Co., Ltd. does not report specific revenue segments, focusing instead on its comprehensive activities in the pharmaceutical industry within China. **Market Cap:** CN¥3.79B Chongqing Lummy Pharmaceutical Co., Ltd. is navigating financial challenges, reporting a net loss of CN¥87.8 million for 2024, up from CN¥8.93 million the previous year, with sales declining to CN¥795.6 million from CN¥895.59 million. Despite being unprofitable, the company has a robust cash position exceeding its total debt and maintains sufficient liquidity to cover both short-term and long-term liabilities comfortably. The management team is experienced with an average tenure of six years, while the board's tenure averages 4.8 years, indicating stability in leadership amidst efforts to reduce losses at a significant rate over five years. - Get an in-depth perspective on Chongqing Lummy Pharmaceutical's performance by reading our balance sheet health report here. - Evaluate Chongqing Lummy Pharmaceutical's historical performance by accessing our past performance report. SZSE:300006 Revenue & Expenses Breakdown as at Apr 2025 ## Hainan Shennong Seed Industry Technology (SZSE:300189) **Simply Wall St Financial Health Rating:** ★★★★☆☆ **Overview:** Hainan Shennong Seed Industry Technology Co., Ltd. operates in the agricultural sector focusing on seed production and distribution, with a market cap of CN¥3.68 billion. **Operations:** Hainan Shennong Seed Industry Technology Co., Ltd. has not reported any specific revenue segments. **Market Cap:** CN¥3.68B Hainan Shennong Seed Industry Technology Co., Ltd. presents a mixed investment profile. The company, with a market cap of CN¥3.68 billion, is currently unprofitable but has managed to reduce its losses by 39.8% annually over the past five years. It maintains a strong liquidity position, with short-term assets of CN¥285.4 million exceeding both short-term and long-term liabilities, and more cash than total debt. However, it faces challenges such as less than one year of cash runway based on current free cash flow and an inexperienced board with an average tenure of 2.9 years. - Dive into the specifics of Hainan Shennong Seed Industry Technology here with our thorough balance sheet health report. - Explore historical data to track Hainan Shennong Seed Industry Technology's performance over time in our past results report. SZSE:300189 Revenue & Expenses Breakdown as at Apr 2025 ## Make It Happen - Take a closer look at our Asian Penny Stocks list of 1,111 companies by clicking here. - Interested In Other Possibilities? The end of cancer? These 21 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ If you're looking to trade Shenzhen Jinjia GroupLtd, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers. With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account. Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer. Sponsored Content ### Related Stocks - [300006.CN](https://longbridge.com/en/quote/300006.CN.md) - [002191.CN](https://longbridge.com/en/quote/002191.CN.md) ## Related News & Research - [CSPC Innovation Pharmaceutical: Biopharma licensing and product launches drove record revenue and profit growth](https://longbridge.com/en/news/296129143.md) - [BlackRock trims MTU Aero Engines voting rights stake to 10.53% from 10.67%](https://longbridge.com/en/news/296074798.md) - [REG - Nomura Intl. PLC Spire Healthcare Grp - Form 8.3 - SPIRE HEALTHCARE GROUP PLC](https://longbridge.com/en/news/296096467.md) - [13:22 ET/C O R R E C T I O N -- Rayence/](https://longbridge.com/en/news/296256530.md) - [15:32 ETMedical Solutions ranks among nation's Top 5 largest healthcare staffing firms](https://longbridge.com/en/news/296139102.md)